Regeneron Pharmaceuticals... (REGN)
NASDAQ: REGN
· Real-Time Price · USD
594.60
-3.56 (-0.60%)
At close: Aug 22, 2025, 12:35 PM
-0.60% (1D)
| Bid | 552.34 |
| Market Cap | 61.94B |
| Revenue (ttm) | 14.21B |
| Net Income (ttm) | 4.46B |
| EPS (ttm) | 39.66 |
| PE Ratio (ttm) | 14.99 |
| Forward PE | 14.6 |
| Analyst | Buy |
| Ask | 650.78 |
| Volume | 516,753 |
| Avg. Volume (20D) | 1,173,450 |
| Open | 602.35 |
| Previous Close | 598.16 |
| Day's Range | 594.02 - 610.42 |
| 52-Week Range | 476.49 - 1211.20 |
| Beta | 0.33 |
About REGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol REGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for REGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Regeneron Pharmaceuticals Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+3.36%
Regeneron Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
2 weeks ago
+2.46%
REGN stock has given up its prior gain. Regeneron Pharmaceuticals shares were trading higher after the company reported better-than-expected Q2 financial results. The company also announced it expects regulatory approvals for its pending FDA EYLEA HD application.
